skip to main content
Idioma:
Resultados 1 2 3 4 next page
Mostrar Somente
Refinado por: data de publicação: 2011Até2018 remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy
Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy

McGowan, Mary P ; Tardif, Jean-Claude ; Ceska, Richard ; Burgess, Lesley J ; Soran, Handrean ; Gouni-Berthold, Ioanna ; Wagener, Gilbert ; Chasan-Taber, Scott Lipinski, Michael

PloS one, 2012-11, Vol.7 (11), p.e49006 [Periódico revisado por pares]

United States: Public Library of Science

Texto completo disponível

Citações Citado por
2
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Raal, Frederick J, Prof ; Stein, Evan A, Prof ; Dufour, Robert, MD ; Turner, Traci, MD ; Civeira, Fernando, MD ; Burgess, Lesley, Prof ; Langslet, Gisle, MD ; Scott, Russell, Prof ; Olsson, Anders G, Prof ; Sullivan, David, MD ; Hovingh, G Kees, MD ; Cariou, Bertrand, MD ; Gouni-Berthold, Ioanna, MD ; Somaratne, Ransi, MD ; Bridges, Ian, MSc ; Scott, Rob, MD ; Wasserman, Scott M, MD ; Gaudet, Daniel, Prof

The Lancet (British edition), 2015-01, Vol.385 (9965), p.331-340 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
3
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
Material Type:
Artigo 		Adicionar ao Meu Espaço

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Blom, Dirk J ; Hala, Tomas ; Bolognese, Michael ; Lillestol, Michael J ; Toth, Phillip D ; Burgess, Lesley ; Ceska, Richard ; Roth, Eli ; Koren, Michael J ; Ballantyne, Christie M ; Monsalvo, Maria Laura ; Tsirtsonis, Kate ; Kim, Jae B ; Scott, Rob ; Wasserman, Scott M ; Stein, Evan A

The New England journal of medicine, 2014-05, Vol.370 (19), p.1809-1819 [Periódico revisado por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponível

Citações Citado por
4
Cardiovascular clinical trials in Africa: opportunities and challenges
Cardiovascular clinical trials in Africa: opportunities and challenges
Material Type:
Artigo 		Adicionar ao Meu Espaço

Cardiovascular clinical trials in Africa: opportunities and challenges

Terblanche, Marli ; Burgess, Lesley

SA heart journal, 2017-04, Vol.8 (2)

South African Heart Association

Texto completo disponível

Citações Citado por
5
APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA
APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA
Material Type:
Artigo 		Adicionar ao Meu Espaço

APOLIPOPROTEIN B SYNTHESIS INHIBITION BY MIPOMERSEN REDUCES LOW-DENSITY LIPOPROTEIN CHOLESTEROL WHEN ADDED TO MAXIMALLY TOLERATED LIPID-LOWERING MEDICATION IN PATIENTS WITH SEVERE HETEROZYGOUS HYPERCHOLESTEROLEMIA

Claude Tardif, Jean ; McGowan, Mary ; Ceska, Richard ; Burgess, Lesley J ; Soran, Handrean ; Gouni-Berthold, Ioanna ; Wagener, Gilbert ; Chasan-Taber, Scott

Journal of the American College of Cardiology, 2011-04, Vol.57 (14), p.E492-E492 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure
Material Type:
Artigo 		Adicionar ao Meu Espaço

Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure

Packer, Milton ; McMurray, John J V ; Desai, Akshay S ; Gong, Jianjian ; Lefkowitz, Martin P ; Rizkala, Adel R ; Rouleau, Jean L ; Shi, Victor C ; Solomon, Scott D ; Swedberg, Karl ; Zile, Michael ; Andersen, Karl ; Arango, Juan Luis ; Arnold, J Malcolm ; Bělohlávek, Jan ; Böhm, Michael ; Boytsov, Sergey ; Burgess, Lesley J ; Cabrera, Walter ; Calvo, Carlos ; Chen, Chen-Huan ; Dukat, Andrej ; Duarte, Yan Carlos ; Erglis, Andrejs ; Fu, Michael ; Gomez, Efrain ; Gonzàlez-Medina, Angel ; Hagège, Albert A ; Huang, Jun ; Katova, Tzvetana ; Kiatchoosakun, Songsak ; Kim, Kee-Sik ; Kozan, Ömer ; Llamas, Edmundo Bayram ; Martinez, Felipe ; Merkely, Bela ; Mendoza, Iván ; Mosterd, Arend ; Negrusz-Kawecka, Marta ; Peuhkurinen, Keijo ; Ramires, Felix J A ; Refsgaard, Jens ; Rosenthal, Arvo ; Senni, Michele ; Sibulo, Jr, Antonio S ; Silva-Cardoso, José ; Squire, Iain B ; Starling, Randall C ; Teerlink, John R ; Vanhaecke, Johan ; Vinereanu, Dragos ; Wong, Raymond Ching-Chiew

Circulation (New York, N.Y.), 2015-01, Vol.131 (1), p.54-61 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
7
The future of the pharmaceutical, biological and medical device industry
The future of the pharmaceutical, biological and medical device industry
Material Type:
Artigo 		Adicionar ao Meu Espaço

The future of the pharmaceutical, biological and medical device industry

Terblanche, Marli ; Burgess, Lesley J

Open Access Journal of Clinical Trials, 2011-09, Vol.3 (default), p.45-50 [Periódico revisado por pares]

Macclesfield: Taylor & Francis Ltd

Texto completo disponível

Citações Citado por
8
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Cannon, Christopher P ; Cariou, Bertrand ; Blom, Dirk ; McKenney, James M ; Lorenzato, Christelle ; Pordy, Robert ; Chaudhari, Umesh ; Colhoun, Helen M

European heart journal, 2015-05, Vol.36 (19), p.1186-1194 [Periódico revisado por pares]

England: Oxford University Press (OUP)

Texto completo disponível

Citações Citado por
9
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease
Material Type:
Artigo 		Adicionar ao Meu Espaço

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease

Yale, J.-F. ; Bakris, G. ; Cariou, B. ; Nieto, J. ; David-Neto, E. ; Yue, D. ; Wajs, E. ; Figueroa, K. ; Jiang, J. ; Law, G. ; Usiskin, K. ; Meininger, G.

Diabetes, obesity & metabolism, 2014-10, Vol.16 (10), p.1016-1027

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por
10
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

Garber, Alan J, Dr, Prof ; King, Allen B, MD ; Prato, Stefano Del, Prof ; Sreenan, Seamus, MD ; Balci, Mustafa K, MD ; Muñoz-Torres, Manuel, Prof ; Rosenstock, Julio, Prof ; Endahl, Lars A, PhD ; Francisco, Ann Marie Ocampo, MD ; Hollander, Priscilla, MD

The Lancet (British edition), 2012-04, Vol.379 (9825), p.1498-1507 [Periódico revisado por pares]

Kidlington: Elsevier Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (31)
  2. Revistas revisadas por pares (22)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (29)
  2. Book Chapters  (2)
  3. Conjunto de Dados  (1)
  4. Livros  (1)
  5. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2012  (5)
  2. 2012Até2012  (5)
  3. 2013Até2013  (3)
  4. 2014Até2015  (11)
  5. Após 2015  (9)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.